Core Laboratories NV (NYSE:CLB) shares saw unusually-strong trading volume on Friday . Approximately 482,205 shares changed hands during mid-day trading, an increase of 3% from the previous session’s volume of 468,934 shares.The stock last traded at $117.17 and had previously closed at $118.24.

Several analysts have recently issued reports on CLB shares. Howard Weil lifted their target price on shares of Core Laboratories NV to $112.00 in a research report on Monday, March 28th. Royal Bank Of Canada reiterated a “buy” rating on shares of Core Laboratories NV in a research report on Saturday, April 23rd. KLR Group reiterated a “buy” rating and issued a $180.00 target price (up previously from $166.00) on shares of Core Laboratories NV in a research report on Monday, June 13th. JPMorgan Chase & Co. restated a “buy” rating on shares of Core Laboratories NV in a research report on Thursday, June 30th. Finally, Zacks Investment Research upgraded shares of Core Laboratories NV from a “hold” rating to a “buy” rating and set a $138.00 price target on the stock in a research report on Wednesday. Three analysts have rated the stock with a sell rating, nine have given a hold rating and eight have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $121.00.

The firm has a market cap of $5.16 billion and a PE ratio of 62.98. The firm has a 50 day moving average of $123.20 and a 200 day moving average of $113.57.

Core Laboratories NV (NYSE:CLB) last posted its earnings results on Wednesday, July 20th. The company reported $0.35 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.35. The business had revenue of $148.10 million for the quarter, compared to analysts’ expectations of $146.37 million. The business’s revenue was down 27.4% compared to the same quarter last year. During the same quarter last year, the business posted $0.81 earnings per share. On average, analysts predict that Core Laboratories NV will post $1.62 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Monday, August 15th. Shareholders of record on Monday, July 18th will be issued a dividend of $0.55 per share. The ex-dividend date is Thursday, July 14th. This represents a $2.20 annualized dividend and a yield of 1.85%.

A number of institutional investors have bought and sold shares of CLB. Aberdeen Asset Management PLC UK acquired a new position in Core Laboratories NV during the fourth quarter valued at $5,554,000. Comerica Bank increased its position in Core Laboratories NV by 1.0% in the fourth quarter. Comerica Bank now owns 23,101 shares of the company’s stock valued at $2,246,000 after buying an additional 239 shares during the period. Poplar Forest Capital LLC increased its position in Core Laboratories NV by 2.7% in the fourth quarter. Poplar Forest Capital LLC now owns 9,650 shares of the company’s stock valued at $1,049,000 after buying an additional 250 shares during the period. Howland Capital Management LLC increased its position in Core Laboratories NV by 4.7% in the fourth quarter. Howland Capital Management LLC now owns 102,070 shares of the company’s stock valued at $11,099,000 after buying an additional 4,562 shares during the period. Finally, WCM Investment Management CA increased its position in Core Laboratories NV by 44.5% in the fourth quarter. WCM Investment Management CA now owns 3,188,453 shares of the company’s stock valued at $346,713,000 after buying an additional 981,243 shares during the period.

Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.